HTB homepage • Conference reports • Articles by subject • Subscribe August 2006 Contents Editorial Volume 7 Number 7/8 July/August 2006 Treatment alerts Dear Doctor letter issued in the U.S. relating to 14 reports of intracranial haemorrhage (ICH) events with tipranavir/r Conference reports 15th International Drug Resistance Workshop, 13-17 June 2006, Sitges, Spain Resistance implications of monotherapy with lopinavir/r (Kaletra) Ritonavir reduces virological failure and resistance in treatment naive patients treated with atazanavir Resistance to darunavir (TMC-114): predicting responses for treatment experienced patients Epidemiological studies and transmission of resistance: evidence for optimism or issues with interpretation? K103N containing variants persist longer in women with subtype D and with higher viral loads No subtype-based differences in baseline levels of K103N-containing variants in women receiving single dose nevirapine Phenotypic NNRTI resistance and genetic diversity in antiretroviral naive women High prevalence of the K65R mutation in Botswana patients treated with ddI/d4T-based regimens Potential for easier selection of K65R mutation with tenofovir pressure in subtype C HIV-1 isolates Categorisation of transmitted HIV drug resistance using the WHO/CDC HIV drug resistance threshold survey method may be useful in resource limited settings Limitations in online tools to identify HIV-1 subtypes Resistance implications from PrEP and microbicide studies in macaques Low-level resistance linked to treatment failure: a role for more sensitive testing for naive patients Testing for resistance after starting treatment Antiretrovirals New formulation of lopinavir/r approved in Europe (Kaletra) and new tradename for access countries (Aluvia) US approval for darunavir (TMC-114, Prezista) Boehringer stops tipranavir trial in treatment-naive patients FDA approves fixed-dose combination of efavirenz/tenofovir/FTC (Atripla): joint company collaboration produces once-daily one pill combination Evidence that CCR5 is protective against West Nile virus: implications for CCR5 inhibitors Treatment access Activists meet with Gilead and Abbott over access to second-line therapy Data exclusivity: a new threat to affordable generic medicines Guidelines Updated US perinatal guidelines (2006) Hepatitis coinfection Efficacy of treatment of acute hepatiitis C in patients with HIV infection Other news HIV transmission, the law and the work of the clinical team: draft recommendations for comment FDA adds last minute clause into package of patient reforms that protects pharmaceutical industry from litigation in cases of side effects On the web Full journal articles with free access and online medical resources Advocacy campaign tools online PDFs Volume 7 Number 7/8 July/August 2006 PDF HTB homepage • Conference reports • Articles by subject • Subscribe
